Skip to main content
. Author manuscript; available in PMC: 2023 Oct 23.
Published in final edited form as: Cell Rep. 2023 Apr 15;42(4):112402. doi: 10.1016/j.celrep.2023.112402

Figure 6. Protective sGP-specific monoclonal antibodies demonstrate elevated binding affinity to sGP and neutrophil phagocytic activity.

Figure 6.

(A) Human IgG1 sGP-specific monoclonal antibodies (n = 58) collected by the Viral Hemorrhagic Fever Immunotherapeutic Consortium were evaluated for the ability to therapeutically protect BALB/c mice 2 days following infection with a mouse-adapted Ebola virus. The protection across all 58 mAbs is shown with the cutoff for protection (60%) is indicated by the dashed line.

(B) Association between the EC50 binding affinity for sGP of each antibody and protection was determined using Spearman rho correlation analysis.

(C) A model using an ensemble of decision trees, applied to antibody features, was predictive of survival as determined by leave-one-out cross validation.

(D) Features were ranked by importance using the permuted predictor delta error from 100 independently constructed models.

(E) Protective and non-protective sGP-specific mAbs were measured for the ability to induce phagocytosis of sGP-coated beads (left) or GP-coated beads (right) by neutrophils. Statistical analysis by Mann-Whitney analysis. ***p < 0.0001.

(F) Protective and non-protective sGP-specific mAbs were measured for the ability to induce phagocytosis of sGP-coated beads (left) or GP-coated beads (right) by monocytes. Statistical analysis by Mann-Whitney analysis. ***p < 0.0001.